Lifileucel: First Approval
Molecular Diagnosis & Therapy · 2024
DOI: 10.1007/s40291-024-00708-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Diagnosis & Therapy, 2024. Verfasst von Susan J Keam. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. mdt@adis.com. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Melanoma, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Lifileucel (AMTAGVI™), a one-time autologous T cell therapy derived and expanded from tumour-infiltrating lymphocytes (TIL) from a patient's own tumour, is being developed by Iovance Biotherapeutics, Inc. for the treatment of cancer. Lifileucel was granted accelerated approval based on objective response rate (ORR) in February 2024 in the USA for use in adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. This article summarizes the milestones in the development of lifileucel leading to this first approval for the treatment of patients with unresectable or metastatic melanoma who have progressed on or after prior anti-PD-1/L1 therapy and targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. mdt@adis.com.
Zitieren
APA
Keam, S. J. (2024). Lifileucel: First Approval. Molecular Diagnosis & Therapy. https://doi.org/10.1007/s40291-024-00708-y
Vancouver
Keam SJ. Lifileucel: First Approval. Molecular Diagnosis & Therapy. 2024. doi:10.1007/s40291-024-00708-y
BibTeX
@article{Keam2024,
author = {Keam, Susan J},
title = {Lifileucel: First Approval},
journal = {Molecular Diagnosis & Therapy},
year = {2024},
doi = {10.1007/s40291-024-00708-y}
}
EUVIMED